Loading
HI
Harrow, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 May 2026.
Harrow, Inc.: what insiders have been doing
Every trade that managers of Harrow, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Nashville, United States. It was founded in 1998. The last twelve months, up to 18 October 2026, brought 10 filings signed by 5 insiders.
Both sides are active: 2 purchases worth €349k and 4 sales worth €3.5M, from 2 insiders and 2 insiders respectively. Netting one side against the other leaves €3.2M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 finance chief and 1 chief executive. Biggest ticket of the year: €2.0M, sold by Opaleye Management Inc. and made public on 5 March 2026.
The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 15 May 2026, 156 days ago. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 10 filings, this issuer sits below that mark. Over the whole record (from 2016), the tally stands at 25 purchases and 16 sales.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
68
Thresholds
n/a
Buy Volume
€9M
25 ops. · all time
Sell Volume
€6M
16 ops. · all time
Who traded when
BuySaleOpaleye Management Inc.11 sales
Amir Shojaei1 sale
Andrew R. Boll1 buy
Mark L. Baum1 buy
Since the insiders bought
- -11.7%Entry US$30.90 · Close 16 Oct 2026 US$27.28
- -11.7%Entry US$30.90 · Close 16 Oct 2026 US$27.28
- +214.2%Entry US$14.34 · Close at T+365 US$45.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Harrow, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$65.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,697 of 24,148 companies
32.8
score / 100
Value34
Quality32
FCF yld4.2%
Earn yld-0.5%
EV/EBITDA30.0x
ROE-116%
Gross mgn75%
Net mgn-1.9%
Debt/EBITDA5.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$27.28
Analyst consensus
9 analystsStrong buy
US$45.00Target US$65.00(+138%)US$88.00
Income statement
RevenueUS$272.3M
Gross profitUS$204.4M75% margin
EBITDAUS$42.5M16% margin
Net income-US$5.1M-13.5% margin
Valuation
PER (forward)9.8x
P/Book67.2x
Beta0.19
Balance sheet & cash
Market capUS$1B
Total debtUS$252M
Free Cash FlowUS$42.8M
Debt / Equity2026%
Profitability & ownership
ROE-116.1%
ROA-0.5%
% insiders15.4%
% institutions58.6%
Last declaration on 21 August 2026
Declarations68 total
11,250 shares@ US$40.000.036% mcap100.0% of flowCOMMON STOCKSEC144:0001493152-26-039748
11,250 shares@ US$40.000.036% mcap52.7% of flowCommon StockSEC:0001493152-26-038807:1
11,250 shares@ US$35.960.032% mcap47.3% of flowCommon StockSEC:0001493152-26-038807:0
3,500 shares@ US$29.900.0077% mcap15.3% of flowCommon StockSEC:0001493152-26-023319:0
Canonical exit: 12 Aug 2026 (T+90)
10,000 shares@ US$30.200.022% mcap12.9% of flowCommon StockSEC:0001493152-26-023321:0
Canonical exit: 12 Aug 2026 (T+90)
59,000 shares@ US$39.152454.9% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-008990:0
5,000 shares@ US$54.186.4% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-008708:0
20,000 shares@ US$53.345725.3% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-26-000965:0
60,000 shares@ US$3.95100.0% of flowCommon StockSEC:0001493152-25-028038:0
180,000 shares@ US$3.9513.0% of flowCommon StockSEC:0001493152-25-028036:0
600,000 shares@ US$7.8787.0% of flowCommon stockSEC:0001641172-25-020751:0
15,204 shares@ US$30.373211.2% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-014709:0
3,000 shares@ US$30.03872.2% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-013799:0
5,000 shares@ US$30.0114.2% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010335:0
10,000 shares@ US$25.89597.1% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010340:0
346,500 shares0Common StockSEC:0001641172-25-003112:0
762,300 shares0Common StockSEC:0001641172-25-003109:0
277,200 shares0Common StockSEC:0001641172-25-003111:0
5,000 shares@ US$30.0114.2% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-000741:0
5,000 shares@ US$29.644.1% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-011028:0
5,000 shares@ US$28.054.1% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-009061:0
20,000 shares@ US$35.590720.8% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-003670:0
90,000 shares@ US$7.3764.1% of flowCommon stockSEC:0001493152-24-036244:0
20,000 shares@ US$9.975.7% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015983:0
Canonical exit: 24 Jul 2024 (T+90)
11,715 shares@ US$10.293.4% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015806:0
Canonical exit: 22 Jul 2024 (T+90)
25 of 68 declarations
About Harrow, Inc.
Harrow, Inc. (NASDAQ: HROW) is a U.S.-based ophthalmology-focused healthcare company operating in a specialized but economically attractive segment of pharmaceuticals. Headquartered in Nashville, Tennessee, in the United States, Harrow was originally founded in 2012 in San Diego, California, and later shifted its corporate center to Nashville as the company expanded. Over time, Harrow has evolved from a business centered on compounded ophthalmic medicines into an integrated platform serving eyecare professionals across surgical, in-office, and chronic-care use cases. ([investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-nashville-expansion/?utm_source=openai))
The company’s operating model is built around ophthalmic disease management solutions for the North American market. Harrow’s portfolio spans conditions affecting both the front and back of the eye, including dry eye disease, ocular inflammation, cataracts, glaucoma, allergic conjunctivitis, infections, and selected retinal indications. The company markets a mix of branded prescription medicines and compounded formulations through its commercial infrastructure and pharmacy relationships. Key products and brands highlighted by Harrow include VEVYE, IHEEZO, IOPIDINE, MAXITROL, MOXEZA, ILEVRO, NEVANAC, MAXIDEX, FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and recently added assets such as BYQLOVI. ([investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Harrow occupies a differentiated position in U.S. ophthalmology because it combines branded products, compounding capabilities, and direct commercial reach. That combination gives the company exposure to both recurring chronic-use therapies and procedure-related products, while also allowing it to support eyecare physicians with a broad product toolkit. Harrow describes itself as a leading provider of ophthalmic disease management solutions in North America and continues to position its platform around affordability, accessibility, and improved clinical outcomes. ([investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai))
Recent corporate developments underscore a deliberate portfolio-expansion strategy. In 2024, Harrow announced the U.S. availability of VEVYE and expanded access through the 340B Prime Vendor Program. In 2025, the company announced the acquisition of U.S. commercial rights to BYQLOVI, a clobetasol propionate ophthalmic suspension positioned as the first new ophthalmic steroid in its class in more than 15 years. These moves support Harrow’s broader effort to deepen its ophthalmic franchise, broaden market access, and strengthen its commercial footprint on the NASDAQ-listed market in the United States. ([investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-availability-vevyer-cyclosporine-ophthalmic/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
